戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d with higher monetary awards than was adult litigation.
2 raging innovation without reducing frivolous litigation.
3 policies, consumer and citizen activism, and litigation.
4  the arrival of family members to protracted litigation.
5 w to best care for patients and prevent such litigation.
6 uations and conditions that commonly lead to litigation.
7 plaintiff and defense experts in malpractice litigation.
8 ucational status, marital status and pending litigation.
9 o reduce the volume and costs of malpractice litigation.
10 e-Davis, and documents were obtained through litigation.
11 ctices also served to shield clinicians from litigation.
12 which involve reputation, reimbursement, and litigation.
13 ease or procedure with the highest amount of litigation.
14  in malpractice cases may fuel inappropriate litigation.
15 k as expert witnesses in medical malpractice litigation.
16 ernal industry documents made public through litigation.
17 , medical diagnostics, and even questions of litigation.
18 d can lead to anger and an increased risk of litigation.
19 of high-risk subgroups for adverse events or litigation.
20 is an important cause of medical malpractice litigation.
21 in the context of toxic tort personal injury litigation.
22 , and involvement in disability-compensation litigation.
23 a management tool for assessing the risks of litigation.
24 n clinical scenario resulting in malpractice litigation.
25 often leads patients to consider malpractice litigation.
26 nclude reimbursement, licensing, and fear of litigation.
27 obability of their becoming involved in such litigation.
28 nd to predict the outcome of future, similar litigation.
29 instances have been central issues in patent litigations.
30 resources, (3) fears of patient disputes and litigation, (4) healthcare funding constraints and high
31                            Common causes for litigation against Mohs surgeons as the primary defendan
32 erstanding outcomes of pediatric malpractice litigation allows ophthalmologists to gain insight into
33 lethal injection through expert testimony in litigation and by publishing evidence of potential aware
34 n; the "sick role," including the effects of litigation and compensation; and the alarming portrayal
35 was used to estimate the association between litigation and homophobic bullying, comparing students i
36            Increasingly it is using domestic litigation and international arbitration to bully LMICs
37 e analysed industry documents released in US litigation and interviewed IARC investigators.
38 e ripe to promote the further growth of this litigation and raise the stakes for research institution
39 e scope and characteristics of qui tam fraud litigation and the whistleblowers who animate this impor
40  the status of functional somatic syndromes, litigation, and a clinical approach that overemphasizes
41 r, dispelling myths about harm, training and litigation, and recognition of the potential for psychol
42 ; challenges to physician authority; fear of litigation; and differing religious, ethnic, or cultural
43                          Medical malpractice litigation appeared in the United States around 1840 for
44            The overhead costs of malpractice litigation are exorbitant.
45 erent ways in which physician scientists and litigation attorneys assess and utilize clinical evidenc
46 re obtained from the National Health Service Litigation Authority through the Freedom of Information
47 izes how end-to-end attribution could inform litigation by assessing whose emissions are responsible
48 garding the long-term history of malpractice litigation can be found in the literature.
49 uency and nature of cases, including year of litigation, certification of provider and operator, type
50                       Overall, the number of litigation claims in ophthalmology is low, relative to t
51  analysis of all public sector ophthalmology litigation claims over a 15-year period in England.
52 cal malpractice system charge that frivolous litigation--claims that lack evidence of injury, substan
53 his discrepancy reflects clinicians' fear of litigation, concern that disclosure might harm patients,
54 Such documents have become available through litigation concerning the promotion of gabapentin (Neuro
55  students in schools that did not experience litigation, controlling for individual and school charac
56 llow-up expenses) and false negatives (e.g., litigation costs stemming from missed diagnoses) in shap
57 Newly produced BAT documents from subsequent litigation, dating from 1996 to 2001 disclose the compan
58                                              Litigation documents reveal that pharmaceutical companie
59 n the United States that has been engaged in litigation due to lack of air conditioning and extreme h
60 es to evaluate the consequences of different litigation efforts aimed at redressing stigma-based harm
61 the cases from the insurers and reviewed the litigation files if the outcome of a case differed from
62 ensure successful, cost-effective defense in litigation for surgeons who use equipment and may suffer
63                                       Recent litigation has led to a situation where preterm cow milk
64                            The potential for litigation has resulted in increased interest in ectasia
65                          Medical malpractice litigation has since been sustained for a century and a
66  overturned, in combination with a threat of litigation, has reduced asbestos use in brake linings.
67    Moreover, the very high costs of asbestos litigation have a significant impact on the whole econom
68 d with increased risk of medical malpractice litigation have been identified, including severity of i
69 luded in this analysis and was compared with litigation in ophthalmology as a whole.
70  A remarkable development in personal injury litigation in recent years involves attempts to expand l
71                               The history of litigation in standards development is also reviewed.
72 his library comprises documents obtained via litigation in the US and does not include documents from
73 ution against the use of these guidelines in litigation in which the clinical decisions of a practiti
74 nst the use of these standards/guidelines in litigation in which the clinical decisions of a practiti
75                  Common scenarios leading to litigation included failure to diagnose or mismanagement
76                      This subset of HIV/AIDS litigation includes testing and reporting; privacy, the
77                                          All litigation involving glaucoma was included in this analy
78 utcomes of ophthalmology medical malpractice litigation involving patients younger than 18 years.
79       Conclusions and Relevance: Malpractice litigation involving pediatric patients was more likely
80 tial use of toxicogenomic data in toxic tort litigation is immense, there is a danger of premature us
81 der existing antitrust doctrine, and lengthy litigation is possible.
82                    This article explains the litigation, its significance and uses it as a backdrop a
83 g Mohs surgery for factors including year of litigation, location, physician specialty, injury sustai
84                     Ongoing False Claims Act litigation may provide greater clarity on billing Medica
85                                   While this litigation may serve a valuable compensation function fo
86 volved anticompetitive settlements in patent litigation (n = 11), unilateral actions by brand manufac
87 rejected methodological pluralism, adopted a litigation (not scientific) model, and was not rigorous.
88               When drawn into other parties' litigation or investigations, journals often receive req
89 case, then such activities may be subject to litigation or prosecutorial action.
90 ns: (1) when and why did medical malpractice litigation originate in the United States and (2) what h
91 We analyzed the prevalence, characteristics, litigation outcomes, and costs of claims that lacked evi
92            Reviewers were not blinded to the litigation outcomes, and the reliability of the error de
93  The vast majority of expenditures go toward litigation over errors and payment of them.
94 d accountability, legislative action, impact litigation, place-based initiatives, education and publi
95                                     The AIDS Litigation Project has reviewed nearly 600 reported case
96 bying, infiltrating government agencies, and litigation; promoting corporate-friendly governance mode
97                     The perception of rising litigation rates is driving the push for patent reform.
98                             The incidence of litigation related to laser surgery shows an increasing
99 iewed documents that became available during litigation related to rofecoxib involving Merck & Co, in
100                                       Recent litigation related to rofecoxib provided a unique opport
101                                  Outcomes of litigation related to sexual orientation-based harassmen
102                       An important subset of litigation relates to HIV/AIDS in the public health and
103 bullying in schools directly involved in the litigation relative to schools that did not experience l
104           Addressing these issues may reduce litigation risk and enhance patient safety surrounding I
105 he same district as the schools experiencing litigation (ROR, 0.76; 95% CI, 0.70-0.81).
106  relative to schools that did not experience litigation (ROR, 0.77; 95% CI, 0.68-0.86).
107                                              Litigation seeking to address alleged violations of the
108 United States now anticipate an onslaught of litigation seeking to overturn federal regulatory action
109                            These benefits of litigation spilled over into schools in the same distric
110 e last 15 years, resulting in an increase of litigations submitted to the legal system.
111 ng to reform the current medical malpractice litigation system.
112 ned an inventory of unsealed federal qui tam litigation targeting health care fraud that was resolved
113  this article, we describe an alternative to litigation that does not predicate compensation on proof
114  high-risk medical specialty with respect to litigation, the urgency, complexity, and invasive nature
115         To assess the ability of malpractice litigation to make accurate determinations, we studied 5
116  original directive, and if necessary to use litigation to prevent implementation of the directive af
117 xtends protection from forced disclosure (in litigation) to health care providers as well as patients
118                             We analyze ERISA litigation trends in 4 areas: professional liability, ut
119 bacco industry documents made public through litigation, triangulated with data from official documen
120 e median plaintiff award for all of glaucoma litigation was $977 476; the median award across all oph
121        Common clinical scenarios in cases of litigation were traumatic ocular injury (15 [22.1%]), re
122       Given the important questions that the litigation will not address, such as the potential costs
123 aw database was reviewed for all malpractice litigation with ophthalmologist defendants in the United
124 mparing students in schools that experienced litigation with students in schools that did not experie
125 by standard medical peer review; the risk of litigation would be constant across the three homogeneou

 
Page Top